The Australian biotech leader CSL Limited is to buy Vifor Pharma Group to beef up its renal presence and move into some adjacent therapeutic areas which, it believes, have high growth potential. The Swiss firm has recently been on an M&A spree itself, bringing more to the table for CSL in the form of Sanifit Therapeutics S.A. and Inositec AG.
Confirmation of the deal – rumors of which had been swirling in the Australian press for a week or so – came on 14 December, when CSL announced it had agreed to pay $179.25 for each Vifor share, valuing the Swiss firm at $11.7bn (AUD$16.4bn), a premium of about 40% to the last closing price of Vifor shares on the SIX on 1 December
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?